Dashboard
1
Poor Management Efficiency with a low ROCE of 8.59%
- The company has been able to generate a Return on Capital Employed (avg) of 8.59% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of -2.41% and Operating profit at -26.85% over the last 5 years
4
With ROE of 4.42%, it has a fair valuation with a 1.93 Price to Book Value
5
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.46%
0%
8.46%
6 Months
-13.0%
0%
-13.0%
1 Year
-11.29%
0%
-11.29%
2 Years
86.95%
0%
86.95%
3 Years
4.17%
0%
4.17%
4 Years
6.56%
0%
6.56%
5 Years
1.46%
0%
1.46%
Shaanxi Meibang Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.41%
EBIT Growth (5y)
-26.85%
EBIT to Interest (avg)
53.25
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.62
Tax Ratio
16.47%
Dividend Payout Ratio
41.67%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.52%
ROE (avg)
7.87%
Valuation key factors
Factor
Value
P/E Ratio
44
Industry P/E
Price to Book Value
1.93
EV to EBIT
39.96
EV to EBITDA
26.86
EV to Capital Employed
2.20
EV to Sales
2.12
PEG Ratio
0.31
Dividend Yield
0.22%
ROCE (Latest)
5.51%
ROE (Latest)
4.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
218.60
195.90
11.59%
Operating Profit (PBDIT) excl Other Income
23.10
8.80
162.50%
Interest
0.10
0.00
Exceptional Items
-0.40
0.70
-157.14%
Consolidate Net Profit
15.40
6.20
148.39%
Operating Profit Margin (Excl OI)
50.00%
3.40%
4.66%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 11.59% vs -0.81% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 148.39% vs 106.67% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
912.00
885.50
2.99%
Operating Profit (PBDIT) excl Other Income
75.00
40.90
83.37%
Interest
0.60
0.20
200.00%
Exceptional Items
-1.00
0.50
-300.00%
Consolidate Net Profit
48.70
36.90
31.98%
Operating Profit Margin (Excl OI)
46.10%
20.90%
2.52%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 2.99% vs 26.68% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 31.98% vs -35.94% in Dec 2024
About Shaanxi Meibang Pharmaceutical Group Co., Ltd. 
Shaanxi Meibang Pharmaceutical Group Co., Ltd.
Chemicals & Petrochemicals
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






